From idea to market: The drug approval process

Journal of the American Board of Family Practice

Volumn 14, Issue 5, 2001, Pages 362-367

  Lipsky, Martin S ^a,b   Sharp, Lisa K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Department of Family Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; LEGAL ASPECT; POLICY; REVIEW; UNITED STATES;

DRUG APPROVAL; PUBLIC POLICY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0035462130     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. US Food and Drug Administration. Frequently asked questions. Available at http://www.fda.gov/ opacom/faqs/faqs.html. Accessed 31 March 2000.
2. Heilman RD. Drug development history, "overview," and what are GCPs? Quality Assur 1995;4: 75-9.
3. Lipsky MS, Waters T. The "prescription-to-OTC switch" movement: its effect on antifungal vaginitis preparations. Arch Fam Med 1999;4:297-300.
4. Gossel EA. Implications of the reclassification of drugs from prescription only to over-the-counter status. Clin Ther 1991;13:200-15.
5. Routledge P. 150 years of pharmacovigilance. Lancet 1998;351:1200-1.
6. Farey D. Benefits vs. risk: how FDA approves new drugs. FDA Consumer Special Report. January 1995. Available at http://www.fda.gov/fdac/special/ newdrug/benefits.html.
7. Leonard EM. Quality assurance and the drug development process: an FDA perspective. Quality Assur 1994;3:178-86.
8. Klees JE, Joines R. Occupational health issues in the pharmaceutical research and development process: Occup Med 1997;12:5-27.
9. Stave GM, Joines R. An overview of the pharmaceutical industry. Occup Med 1997;12:1-4.
10. Pharmaceutical Research and Manufacturers of America Publication. 21 December 2000. Available at http://www.phrma.org.
11. Cancer Trials: New drugs, new drug uses, and clinical trails. In: National Cancer Institute. Understanding trials. Posted 29 July 1999. Available at http://cancertrials.nci.nih.gov/understanding/indepth/fda/trials.html.
12. Walters PG. FDA's new drug evaluation process: a general overview. J Public Health Dent 1992;52: 333-7.
13. The FDA Modernization Act of 1997. (BG no 97-13.) FDA Backgrounder 21 November 1997. Available at http://www.fda.gov/opacom/backgrounders/ modact.htm.
14. Marwick C. Concern expressed about FDA reform legislation. JAMA 1997;278:459.
15. Kleinke JD, Gottlieb S. Is the FDA approving drugs too fast? Probably not - but drug recalls have sparked debate. BMJ 1998;317:899.
16. Landow L. FDA approves drug even when experts on its advisory panels raise safety questions. BMJ 1999;318:944.
17. Lurie P, Sasich LD. Safety of FDA-approved drugs. JAMA 1999;282:2297.
18. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass A, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281:1728-34.